Jenburkt Pharmaceuticals Ltd

BSE: 524731
Jenburkt Pharmaceuticals Ltd - pharma in Mumbai, Maharashtra, India. FY 2026 financials and compliance.
CIN L24230MH1985PLC036541 Incorporated 10 June 1985 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - BSE: 524731 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹168.74 Cr
▲ 11.24% YoY
Computed EBITDA · FY 2026
₹54.04 Cr
▲ 14.7% YoY
Net profit · FY 2026
₹34.74 Cr
▲ 8.34% YoY
Authorised capital
₹10 Cr
Registered with MCA
Paid-up capital
₹4.41 Cr
Issued & subscribed
Open charges
₹2.03 Cr
Satisfied ₹16.17 Cr
Company age
41 yrs
Est. 1985
Employees · EPFO
765
Latest available

About Jenburkt Pharmaceuticals Ltd

Data last updated: 14 July 2026

Jenburkt Pharmaceuticals Ltd is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 10 June 1985, the company has been in operation for over 41 years.

Registered with ROC Mumbai under CIN L24230MH1985PLC036541. Listed on BSE: 524731.

Capital: an authorised share capital of ₹10 Cr and a paid-up capital of ₹4.41 Cr. Formerly known as Jen Burkt Pharmaceuticals Private Limited. It is led by directors including Hina Ravindra Mehta and Dilip Harkishandas Bhuta.

Last AGM: 18 July 2025. Financial statements filed for year ended 31 March 2025. Office: Nirmala Apts 93 Jay Prakash Rd Andheri W, Mumbai, Maharashtra, India – 400058.

As per BSE-filed standalone financials for FY 2026, the company reported a revenue of ₹168.74 Cr, a growth of 11.24% compared to the previous year. The net worth stands at ₹197.04 Cr (up 14.71% YoY). Total assets are valued at ₹226.01 Cr (up 15.2% YoY).

The company has a workforce of approximately 765 employees as per the latest available data.

The company is associated with 2 brands - Jenburkt Wellness, Jenburkt. As per MCA filings, the company has open charges of ₹2.03 Cr and satisfied charges of ₹16.17 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website jenburkt.com.

Company Details of Jenburkt Pharmaceuticals Ltd
CIN L24230MH1985PLC036541
Registration Number 036541
Incorporation Date 10 June 1985
ROC Mumbai
Listing Status Listed (BSE: 524731)
Company Status Active
Date of Last AGM 18 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Ashish Uttam Bhuta Managing Director Dilip Harkishandas Bhuta Whole-Time Director Hina Ravindra Mehta Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    jenburkt.com
  • Social Media
  • Registered Address
    Nirmala Apts 93 Jay Prakash Rd Andheri W, Mumbai, Maharashtra, India – 400058
  • Industry
    Pharma, Drug Formulation & Development
Company report
Jenburkt Pharmaceuticals Ltd - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Jenburkt Pharmaceuticals Ltd report

Financials, compliance, directors, charges, ownership and filings for Jenburkt Pharmaceuticals Ltd in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd has one previous CIN (Corporate Identification Number): U24230MH1985PLC036541. The current CIN is L24230MH1985PLC036541, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24230MH1985PLC036541 Current
U24230MH1985PLC036541 Previous

Associated Brands with Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd operates two associated brands: Jenburkt Wellness and Jenburkt. These brands represent Jenburkt Pharmaceuticals Ltd's diversified market presence and brand portfolio.

Brand Description Website
Jenburkt
Manufacturer of pharmaceutical formulations and prescription medications jenburkt.com
Jenburkt Wellness
Wellness and pharmaceutical product development in India. jenburktwellness.com

Business Activity of Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Jenburkt Pharmaceuticals Ltd

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd is audited by D.R.Mehta & Associates (ICAI peer reviewed, certificate valid till 2028-03-31) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
D.R.Mehta & Associates (ICAI peer reviewed, certificate valid till 2028-03-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd is currently managed by 6 directors, with 8 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Hina Ravindra Mehta Director 28 Mar 2020 6 Years 4 Months Current
Dilip Harkishandas Bhuta
Also directs: Bhuta Holdings Private Limited
Whole-Time Director 16 Jul 2013 13 Years 1 Months Current
Ashish Uttam Bhuta
Also directs: Bhuta Holdings Private Limited
Managing Director 02 Jun 2007 19 Years 2 Months Current
Pankaj Arun Dantwala
Also directs: Clover Infoservices Private Limited, Kalzoom Technologies Private Limited, Kalzoom Management Service Technologies Private Limited
Director 28 May 2024 2 Years 2 Months Current
Krishnan Subharaman Director 28 May 2024 2 Years 2 Months Current
Sumit Ajaybhai Thakkar Director 26 Jul 2023 3 Years 0 Months Current
View all directors

Financials of Jenburkt Pharmaceuticals Ltd FY 2026 filings available

Jenburkt Pharmaceuticals Ltd reported revenue of ₹168.74 Cr (up 11.24% YoY) for FY 2026.

Revenue · FY 2026
₹168.74 Cr ▲ 11.24%
Profit · FY 2026
₹34.74 Cr ▲ 8.34%
Computed EBITDA · FY 2026
₹54.04 Cr ▲ 14.7%
Revenue₹ Cr · Standalone0100200FY 2019: ₹123 Cr123FY 2019FY 2020: ₹119 Cr · -3.1% YoY119-3.1%FY 2020FY 2021: ₹109 Cr · -8.1% YoY109-8.1%FY 2021FY 2022: ₹124 Cr · +13.4% YoY124+13.4%FY 2022FY 2023: ₹137 Cr · +10.3% YoY137+10.3%FY 2023FY 2024: ₹142 Cr · +3.8% YoY142+3.8%FY 2024FY 2025: ₹152 Cr · +6.9% YoY152+6.9%FY 2025FY 2026: ₹169 Cr · +11.2% YoY169+11.2%FY 2026
Net Profit₹ Cr · Standalone02040FY 2019: ₹20 Cr19.8FY 2019FY 2020: ₹15 Cr · -24.9% YoY14.9-24.9%FY 2020FY 2021: ₹17 Cr · +11% YoY16.5+11%FY 2021FY 2022: ₹22 Cr · +35.1% YoY22.3+35.1%FY 2022FY 2023: ₹25 Cr · +10.4% YoY24.6+10.4%FY 2023FY 2024: ₹26 Cr · +5.6% YoY26+5.6%FY 2024FY 2025: ₹32 Cr · +23.4% YoY32.1+23.4%FY 2025FY 2026: ₹35 Cr · +8.3% YoY34.7+8.3%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0204060Q1'25: ₹33 Cr32.5Q1'25Q2'25: ₹41 Cr41.2Q2'25Q3'25: ₹37 Cr36.9Q3'25Q4'25: ₹41 Cr41Q4'25Q1'26: ₹36 Cr · +9.2% YoY35.5+9.2%Q1'26Q2'26: ₹46 Cr · +10.5% YoY45.6+10.5%Q2'26Q3'26: ₹43 Cr · +16.6% YoY43+16.6%Q3'26Q4'26: ₹45 Cr · +8.7% YoY44.6+8.7%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue from Operations ₹168.74 Cr ₹151.69 Cr ₹141.97 Cr ₹136.75 Cr ₹123.98 Cr ₹109.29 Cr ₹118.89 Cr ₹122.64 Cr
Other Income ₹10.3 Cr ₹6.72 Cr ₹4.67 Cr ₹5.12 Cr ₹4.95 Cr ₹4.31 Cr ₹4.22 Cr ₹3.41 Cr
Total Income ₹179.04 Cr ₹158.41 Cr ₹146.63 Cr ₹141.87 Cr ₹128.93 Cr ₹113.6 Cr ₹123.11 Cr ₹126.05 Cr
Cost of Materials Consumed ₹8.99 Cr ₹8.51 Cr ₹8.39 Cr ₹11.12 Cr ₹11.74 Cr ₹6.78 Cr ₹9.65 Cr ₹11.84 Cr
Purchases of Stock-in-Trade ₹28.18 Cr ₹21.26 Cr ₹22.41 Cr ₹20.55 Cr ₹21.98 Cr ₹20.13 Cr ₹23.9 Cr ₹26.91 Cr
Changes in Inventories -₹4.85 Cr -₹11.55 Lakh -₹39.29 Lakh ₹1.34 Cr -₹2.28 Cr ₹3.18 Cr -₹48.74 Lakh -₹2.49 Cr
Employee Benefit Expense ₹49.88 Cr ₹45.54 Cr ₹42.49 Cr ₹38.81 Cr ₹36.49 Cr ₹32.38 Cr ₹36.51 Cr ₹31.2 Cr
Finance Costs ₹46.2 Lakh ₹45.28 Lakh ₹27.07 Lakh ₹36.7 Lakh ₹43.45 Lakh ₹47.37 Lakh ₹52.56 Lakh ₹38.59 Lakh
Depreciation & Amortisation ₹3.11 Cr ₹2.73 Cr ₹2.34 Cr ₹2.26 Cr ₹1.9 Cr ₹2.04 Cr ₹2.3 Cr ₹1.35 Cr
Other Expenses ₹42.79 Cr ₹36.11 Cr ₹35.95 Cr ₹34.57 Cr ₹28.8 Cr ₹26.98 Cr ₹29.57 Cr ₹30.22 Cr
Total Expenses ₹128.57 Cr ₹114.48 Cr ₹111.46 Cr ₹109.01 Cr ₹99.06 Cr ₹91.96 Cr ₹101.97 Cr ₹99.42 Cr
Profit Before Exceptional Items & Tax ₹50.47 Cr ₹43.93 Cr ₹35.18 Cr ₹32.86 Cr ₹29.87 Cr ₹21.64 Cr ₹21.14 Cr ₹26.63 Cr
Exceptional Items -₹3.95 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹46.52 Cr ₹43.93 Cr ₹35.18 Cr ₹32.86 Cr ₹29.87 Cr ₹21.64 Cr ₹21.14 Cr ₹26.63 Cr
Total Tax Expense ₹11.78 Cr ₹11.87 Cr ₹9.2 Cr ₹8.26 Cr ₹7.57 Cr ₹5.14 Cr ₹6.27 Cr ₹6.84 Cr
Net Profit ₹34.74 Cr ₹32.06 Cr ₹25.98 Cr ₹24.61 Cr ₹22.3 Cr ₹16.5 Cr ₹14.87 Cr ₹19.8 Cr
Other Comprehensive Income -₹1.53 Cr ₹1.53 Cr ₹2.93 Cr ₹42.26 Lakh ₹1.3 Cr ₹1.96 Cr -₹2.33 Cr -₹27.29 Lakh
Total Comprehensive Income ₹33.21 Cr ₹33.59 Cr ₹28.91 Cr ₹25.03 Cr ₹23.6 Cr ₹18.46 Cr ₹12.54 Cr ₹19.52 Cr
EBITDA (computed) ₹54.04 Cr ₹47.11 Cr ₹37.79 Cr ₹35.49 Cr ₹32.2 Cr ₹24.15 Cr ₹23.96 Cr ₹28.37 Cr
Basic EPS ₹78.71 ₹72.65 ₹58.86 ₹53.90 ₹48.58 ₹35.96 ₹32.40 ₹43.14
Diluted EPS ₹78.71 ₹72.65 ₹58.86 ₹53.90 ₹48.58 ₹35.96 ₹32.40 ₹43.14
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Total Assets ₹226.01 Cr ₹196.19 Cr ₹165.1 Cr ₹141.81 Cr ₹142.95 Cr ₹120.38 Cr ₹104.07 Cr ₹102.82 Cr
Non-current Assets ₹130.92 Cr ₹139.65 Cr ₹55.37 Cr ₹60.72 Cr ₹67.05 Cr ₹40.46 Cr ₹14.53 Cr ₹13.16 Cr
Current Assets ₹95.09 Cr ₹56.53 Cr ₹109.73 Cr ₹81.09 Cr ₹75.9 Cr ₹79.92 Cr ₹89.54 Cr ₹89.67 Cr
Property, Plant & Equipment ₹19.22 Cr ₹14.43 Cr ₹9.97 Cr ₹10.26 Cr ₹9.95 Cr ₹8.51 Cr ₹8.9 Cr ₹9.43 Cr
Inventories ₹13.63 Cr ₹8.88 Cr ₹8.56 Cr ₹8.34 Cr ₹9.89 Cr ₹7.58 Cr ₹10.9 Cr ₹9.83 Cr
Trade Receivables ₹24.36 Cr ₹20.73 Cr ₹19.48 Cr ₹16.96 Cr ₹15.21 Cr ₹14 Cr ₹17.83 Cr ₹22.89 Cr
Cash & Equivalents ₹5.58 Cr ₹7.36 Cr ₹4.13 Cr ₹3.66 Cr ₹5.03 Cr ₹2.49 Cr ₹2.53 Cr ₹1.23 Cr
Equity (Net Worth) ₹197.04 Cr ₹171.78 Cr ₹144.94 Cr ₹122.39 Cr ₹117.38 Cr ₹98.47 Cr ₹80 Cr ₹77.47 Cr
Equity Share Capital ₹4.41 Cr ₹4.41 Cr ₹4.41 Cr ₹4.41 Cr ₹4.59 Cr ₹4.59 Cr ₹4.59 Cr ₹4.59 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹0 ₹1.98 Cr ₹0 ₹2.44 Cr ₹5.82 Cr ₹3.71 Cr ₹3.44 Cr ₹7.47 Cr
Total Debt (computed) ₹0 ₹1.98 Cr ₹0 ₹2.44 Cr ₹5.82 Cr ₹3.71 Cr ₹3.44 Cr ₹7.47 Cr
Current Liabilities ₹23.15 Cr ₹18.82 Cr ₹16.38 Cr ₹15.76 Cr ₹21.28 Cr ₹17.93 Cr ₹19.8 Cr ₹22.62 Cr
Total Liabilities ₹28.97 Cr ₹24.41 Cr ₹20.16 Cr ₹19.42 Cr ₹25.57 Cr ₹21.91 Cr ₹24.07 Cr ₹25.36 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹26.52 Cr ₹27.91 Cr ₹8.12 Cr ₹17.05 Cr ₹9.4 Cr
Investing Cash Flow -₹19.45 Cr -₹17.04 Cr -₹58.04 Lakh ₹2.62 Cr -₹1.33 Cr
Financing Cash Flow -₹8.86 Cr -₹7.62 Cr -₹7.08 Cr -₹21.04 Cr -₹5.53 Cr
Capital Expenditure ₹13.72 Cr ₹19.71 Cr ₹2.55 Cr ₹2.1 Cr ₹3.05 Cr
Free Cash Flow (computed) ₹12.8 Cr ₹8.19 Cr ₹5.57 Cr ₹14.95 Cr ₹6.35 Cr
Dividends Paid ₹7.94 Cr ₹6.78 Cr ₹6.32 Cr ₹5.5 Cr ₹4.68 Cr
Net Change in Cash -₹1.79 Cr ₹3.24 Cr ₹46.55 Lakh -₹1.37 Cr ₹2.54 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25
Revenue from Operations ₹44.63 Cr ₹43.02 Cr ₹45.56 Cr ₹35.53 Cr ₹41.05 Cr ₹36.89 Cr ₹41.22 Cr ₹32.54 Cr
Other Income ₹4.35 Cr ₹1.82 Cr ₹2.08 Cr ₹2.06 Cr ₹1.88 Cr ₹1.58 Cr ₹1.85 Cr ₹1.41 Cr
Total Income ₹48.98 Cr ₹44.84 Cr ₹47.64 Cr ₹37.58 Cr ₹42.93 Cr ₹38.47 Cr ₹43.07 Cr ₹33.94 Cr
Cost of Materials Consumed ₹2.19 Cr ₹2.47 Cr ₹2.19 Cr ₹2.14 Cr ₹2.28 Cr ₹2.24 Cr ₹2.15 Cr ₹1.84 Cr
Purchases of Stock-in-Trade ₹8.7 Cr ₹7.83 Cr ₹6.28 Cr ₹5.37 Cr ₹5.25 Cr ₹4.93 Cr ₹5.33 Cr ₹5.75 Cr
Changes in Inventories -₹2.23 Cr -₹1.51 Cr -₹12.04 Lakh -₹99.02 Lakh ₹37.16 Lakh ₹87,000 ₹80.42 Lakh -₹1.3 Cr
Employee Benefit Expense ₹9.52 Cr ₹14.71 Cr ₹13.93 Cr ₹11.72 Cr ₹11.43 Cr ₹10.92 Cr ₹12.52 Cr ₹10.67 Cr
Finance Costs ₹12.92 Lakh ₹11.55 Lakh ₹10.74 Lakh ₹10.99 Lakh ₹11.13 Lakh ₹11.03 Lakh ₹11.64 Lakh ₹11.48 Lakh
Depreciation & Amortisation ₹80.88 Lakh ₹83.25 Lakh ₹74.39 Lakh ₹72.25 Lakh ₹79.13 Lakh ₹77.86 Lakh ₹63.9 Lakh ₹51.9 Lakh
Other Expenses ₹12.21 Cr ₹12.09 Cr ₹10.16 Cr ₹8.33 Cr ₹10.85 Cr ₹9.97 Cr ₹8.99 Cr ₹6.29 Cr
Total Expenses ₹31.32 Cr ₹36.54 Cr ₹33.3 Cr ₹27.4 Cr ₹31.09 Cr ₹28.96 Cr ₹30.55 Cr ₹23.88 Cr
Profit Before Exceptional Items & Tax ₹17.66 Cr ₹8.3 Cr ₹14.33 Cr ₹10.18 Cr ₹11.84 Cr ₹9.51 Cr ₹12.52 Cr ₹10.06 Cr
Exceptional Items -₹3.95 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹13.71 Cr ₹8.3 Cr ₹14.33 Cr ₹10.18 Cr ₹11.84 Cr ₹9.51 Cr ₹12.52 Cr ₹10.06 Cr
Total Tax Expense ₹2.86 Cr ₹2.37 Cr ₹4.17 Cr ₹2.39 Cr ₹3.3 Cr ₹3.01 Cr ₹2.92 Cr ₹2.65 Cr
Net Profit ₹10.85 Cr ₹5.93 Cr ₹10.16 Cr ₹7.79 Cr ₹8.54 Cr ₹6.51 Cr ₹9.6 Cr ₹7.42 Cr
Other Comprehensive Income -₹3.21 Cr ₹59.21 Lakh -₹28.13 Lakh ₹1.37 Cr -₹45.15 Lakh -₹57.59 Lakh ₹1.01 Cr ₹1.55 Cr
Total Comprehensive Income ₹7.64 Cr ₹6.52 Cr ₹9.88 Cr ₹9.17 Cr ₹8.09 Cr ₹5.93 Cr ₹10.61 Cr ₹8.97 Cr
EBITDA (computed) ₹18.6 Cr ₹9.24 Cr ₹15.18 Cr ₹11.01 Cr ₹12.74 Cr ₹10.4 Cr ₹13.28 Cr ₹10.7 Cr
Basic EPS ₹24.58 ₹13.44 ₹23.03 ₹17.66 ₹19.34 ₹14.75 ₹21.75 ₹16.80
Diluted EPS ₹24.58 ₹13.44 ₹23.03 ₹17.66 ₹19.34 ₹14.75 ₹21.75 ₹16.80
Latest 8 quarters shown.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Jenburkt Pharmaceuticals Ltd. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Jenburkt Pharmaceuticals Ltd

As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 46.64%, domestic institutional investors hold 0.12%, retail and other public shareholders hold 53.25% of Jenburkt Pharmaceuticals Ltd. The company had 6,999 shareholders on record.

Promoters: 46.64%DII (Domestic Institutional): 0.12%Retail & Others: 53.25%
Mar 2026
QUARTER
46.64% Promoters
0.12% DII (Domestic Institutional)
53.25% Retail & Others
Promoter holding - history
Now 46.64% · Mar 2026High 47.56% · Jun 2023Low 46.64% · Mar 2026
45%46%47%48%49%Jun 2023Dec 2023Jun 2024Dec 2024Jun 2025Dec 2025Jun 2023: 47.56%Sep 2023: 47.42%Dec 2023: 47.39%Mar 2024: 47.23%Jun 2024: 46.71%Sep 2024: 46.71%Dec 2024: 46.69%Mar 2025: 46.68%Jun 2025: 46.67%Sep 2025: 46.66%Dec 2025: 46.65%Mar 2026: 46.64%47.56%46.64%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters46.64%46.65%46.66%46.67%46.68%46.69%
Public53.36%53.35%53.34%53.33%53.32%53.31%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024
Promoters46.64%46.68%47.23%
Public53.36%53.32%52.77%
Promoter change (YoY, %pts)-0.04-0.55-

Charges & Borrowings of Jenburkt Pharmaceuticals Ltd

Open charges
₹2.03 Cr
Satisfied charges
₹16.17 Cr
Breakdown by lending institutions
Others₹2.03 Cr
Latest charge details
DateLenderAmountStatus
21 Nov 2022 Others ₹1 Lakh Open
21 Nov 2022 Others ₹2 Lakh Open
21 Nov 2022 Others ₹2 Cr Open
02 Dec 2022 Others ₹3 Cr Satisfied
21 Oct 2022 Others ₹1.5 Lakh Satisfied

Total charge records: 12 View all charges

Employees and EPFO Compliance at Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd has a workforce of 765 employees as of Apr 10, 2024.

Employee count
765
Active EPFO establishments
2
Employee growth
1.59%
Premium access

Employee and EPFO history for Jenburkt Pharmaceuticals Ltd

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Jenburkt Pharmaceuticals Ltd

Premium access

GST registrations and filing compliance for Jenburkt Pharmaceuticals Ltd

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Jenburkt Pharmaceuticals Ltd

Premium access

Credit ratings, litigation, and regulatory alerts for Jenburkt Pharmaceuticals Ltd

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Jenburkt Pharmaceuticals Ltd

Premium access

MSME payment history for Jenburkt Pharmaceuticals Ltd

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Jenburkt Pharmaceuticals Ltd

Premium access

Corporate group structure for Jenburkt Pharmaceuticals Ltd

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Jenburkt Pharmaceuticals Ltd

Premium access

MCA filings and documents for Jenburkt Pharmaceuticals Ltd

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Jenburkt Pharmaceuticals Ltd

Charges
29 Oct 2025
A charge registered on 28 Aug 2019 via Charge ID 100289026 with Others was fully satisfied on 29 Oct 2025.
Activity
18 Jul 2025
Jenburkt Pharmaceuticals Ltd last Annual general meeting of members was held on 18 Jul 2025 as per latest MCA records.
Activity
31 Mar 2025
Jenburkt Pharmaceuticals Ltd has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Charges
22 Jan 2025
A charge registered on 21 Oct 2022 via Charge ID 100627860 with Others was fully satisfied on 22 Jan 2025.
Directors
28 May 2024
Pankaj Arun Dantwala was appointed as a Director on 28 May 2024 & has been associated with this company since 2 years 2 months.
Directors
28 May 2024
Krishnan Subharaman was appointed as a Director on 28 May 2024 & has been associated with this company since 2 years 2 months.

Recent News on Jenburkt Pharmaceuticals Ltd

Frequently Asked Questions about Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 10 June 1985 (41+ years old) and is registered under CIN L24230MH1985PLC036541. Listed on BSE: 524731. The company has 765 employees.

Jenburkt Pharmaceuticals Ltd reported revenue of ₹168.74 Cr for FY 2026 (up 11.24% YoY) based on standalone BSE filings.

The current directors of Jenburkt Pharmaceuticals Ltd are:

The primary industry of Jenburkt Pharmaceuticals Ltd is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Jenburkt Pharmaceuticals Ltd is listed on BSE with code 524731.

Jenburkt Pharmaceuticals Ltd can be reached at the registered office: Nirmala Apts 93 Jay Prakash Rd Andheri W, Mumbai, Maharashtra, India – 400058, or through the website jenburkt.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available